Saros Website
9 employees on LinkedIn · 1 known investors
Saros is a biopharmaceutical company developing immunotherapies based on a proprietary lipid nanoparticle platform that targets innate immune cells to activate immune responses. Its treatments are aimed at patients with cancer and auto-immune diseases.
Investors · 1
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Saros Website do?
- Saros is a biopharmaceutical company developing immunotherapies based on a proprietary lipid nanoparticle platform that targets innate immune cells to activate immune responses. Its treatments are aimed at patients with cancer and auto-immune diseases.
- Who are Saros Website's investors?
- Saros Website's investors include SmartHealth Catalyzer.